Elucid is a Boston-based medical technology company specializing in AI-powered imaging analysis software for cardiovascular disease assessment. Their flagship product, PlaqueIQ™, is the first and only non-invasive software validated against histopathology to quantify arterial plaque characteristics, including lipid-rich necrotic core, calcification, and intraplaque hemorrhage. This technology enables physicians to make more precise, personalized treatment decisions for patients with known or suspected cardiovascular disease .

Company Overview

• 
  

  Founded: 2013

  
  


• 
  

  Headquarters: 399 Boylston Street, Suite 400, Boston, MA 02116, USA

  
  


• 
  

  Alternate Address: 225 Main Street, Suite 15, Wenham, MA 01984, USA

  
  


• 
  

  Phone: +1-617-329-9487

  
  


• 
  

  Email: info@elucid.com

  
  


• 
  

  Website: elucid.com

  
  

Leadership Team

• 
  

  Kelly Huang, PhD – President & CEO

  
  


• 
  

  Blake Richards – Chief Operating Officer

  
  


• 
  

  Andrew Miller – Chief Technology Officer & SVP, Engineering

  
  


• 
  

  Windi Hary – Chief Regulatory & Quality Officer

  
  


• 
  

  Sophie Khem – SVP, Clinical Quality & Delivery

  
  


• 
  

  Amy Kruglak – SVP, People & Leadership Development

  
  


• 
  

  Kevin Mathews – SVP, Marketing

  
  


• 
  

  Amir Ahmadi, MD – Chief Scientific Advisor

  
  

Recent Developments

• 
  

  In November 2023, Elucid raised $80 million in a Series C funding round led by Elevage Medical Technologies to accelerate the commercialization of its AI-powered diagnostic tools .

  
  


• 
  

  The company received FDA 510(k) clearance for its PlaqueIQ™ image analysis software in October 2024, marking it as the first software validated on ground-truth histology for plaque characterization .

  
  


• 
  

  Elucid has expanded its leadership team and moved into new headquarters in Boston to support its growth and the upcoming commercial launch of PlaqueIQ™